Request a quote

GMP Oncolytic Virus Manufacturing

Oncolytic virus manufacturing platform services with experience producing vaccinia virus, adenovirus, and herpesvirus oncolytic vector systems.

Request a Consultation

Oncolytic Virus Manufacturing Platform

As a leading oncolytic virus CDMO, we support seed virus production, tech transfer, process and analytical method development, clinical GMP manufacturing, and aseptic fill and finish.

Oncolytic Virus Platform Highlights

Exceptional Expertise

Various oncolytic virus manufacturing cell lines, adherent and suspension cells
Extensive experience with adenovirus, herpes simplex virus, and vaccinia virus productions
10+ Batches of GMP vaccinia virus vector productions

Platform Technology

Cell & virus banking, master and working banks
Optimized processes, streamlined upstream & downstream processes
Scalable production process, up to 200L

Client-Centric Partnership

Flexible and tailored the processes to accommodate your needs
Proactive in scientific and regulatory support

Excellence in Quality

Robust QMS system
Full spectrum in-house quality testing
Compliance with FDA/EMA/NMPA requirements

Oncolytic Virus CDMO Services

Service Timeline Price
Research grade & preclinical oncolytic virus productions 2-3 Weeks Please Inquire
GMP grade oncolytic virus process development, production, and QC testing Please Inquire

Let uBriGene Support Your Oncolytic Virus Production

Comprehensive oncolytic virus CDMO services

Client oriented partnership

Ask the Expert
ubriGene's oncolytic virus CDMO workflow.

QC Release Assays

Test Item Method
Physical/Chemical Properties Appearance Visual inspection
pH pH measurement
Identity Sequencing Sanger/NGS
Target Protein Western Blot
Morphology and Structure EM
Titer Genome Titer(vg) qPCR
Infectious Titer(PFU) Plaque Assay
Purity Purity AUC
Potency Target Cell Killing CCK8 assay
Tumor Specificity CCK8 assay
Virus Replication Plaque Assay
Target Protein Expression WB/ELISA
Residuals Host Protein Residuals ELISA
Host DNA Residuals qPCR
Nuclease Residuals ELISA
E1A Residuals qPCR
Safety Sterility Membrane Filtration
Mycoplasma qPCR
Wild Type Virus Sanger sequencing

*Outsourced testing

Request a Consultation

GMP Oncolytic Virus Validation Data

High-quality Adenovirus Produced After Chromatographic Purification

High-quality adenovirus elution profile after AEX chromatographic purification.

High-quality Vaccina Virus Produced After Chromatographic Purification

Chromatographic purification plot depicting the high-quality vaccinia produced.

Frequently asked questions

The timeline for a GMP oncolytic virus program depends on virus type, starting material, cell substrate, process development, analytical methods, manufacturing scale, and regulatory testing. uBriGene indicates that Master Virus Bank (MVB) preparation can take approximately one month, while the complete development-to-GMP timeline depends on the individual program scope.

uBriGene currently reports an overall final recovery of approximately 30% after sterile filtration for its GMP oncolytic virus manufacturing process. Actual recovery depends on the virus type, production process, purification strategy, formulation, and filtration conditions, so recovery should be evaluated using a defined product-specific measurement such as infectious titer or genome titer.

Yes. uBriGene supports oncolytic virus programs from research and preclinical development through GMP manufacturing. Services can include process development, analytical method development, cell and virus banking, technology transfer, scale-up, GMP production, QC testing, and regulatory support according to program requirements.

Oncolytic virus therapy uses viruses that are engineered or selected to preferentially infect and destroy tumor cells while also potentially stimulating antitumor immune responses. The degree of tumor selectivity and safety depends on the specific viral platform, genetic design, target tumor, dose, and administration strategy.

uBriGene supports manufacturing of multiple oncolytic virus platforms, including adenovirus, herpes simplex virus (HSV), and vaccinia virus. uBriGene has completed 10+ GMP vaccinia-virus manufacturing batches.

uBriGene supports both adherent and suspension host-cell systems, with the cell substrate selected according to the specific oncolytic virus and manufacturing process. For example, uBriGene's vaccinia-virus development work has used its 293XS suspension-cell platform, which has been evaluated for scalability and process control.

Yes. uBriGene supports process development and scale-up for oncolytic virus manufacturing, with its platform currently supporting production scales up to 200 L. The appropriate scale and process configuration depend on the virus, host cell, production method, target batch size, and clinical requirements.

uBriGene supports GMP oncolytic virus programs within quality systems designed to meet applicable regulatory requirements for the intended development program and market. Support can include controlled manufacturing, analytical testing, documentation, and regulatory support according to program requirements. The Germantown, Maryland facility maintains FDA DMF #31266, and products tested at the site have supported FDA IND submissions and clearances.

uBriGene's oncolytic virus platform includes cell and virus banking, Master and Working Cell Banks, process development, optimized upstream and downstream manufacturing processes, analytical method development, QC testing, scale-up, and sterile fill/finish. The specific workflow is adapted to the virus platform and manufacturing requirements.

uBriGene supports early-stage oncolytic virus development with cell and virus banking, process development, analytical method development, and technology transfer. These activities help establish a manufacturable and scalable process before GMP production, with development plans tailored to the virus, host cell, and intended application.

uBriGene supports product-specific analytical and QC testing covering identity, morphology, genome and infectious titer, purity, potency, tumor specificity, target-protein expression, residual host-cell DNA and proteins, nuclease residuals, sterility, mycoplasma, and wild-type virus testing where applicable. Assays may include sequencing, qPCR, plaque assays, CCK8-based functional assays, Western blot/ELISA, AUC, and other qualified methods according to the virus and intended application.

Oncolytic virus potency is typically assessed using a functional assay that measures the product's intended biological activity, such as tumor-cell killing or tumor-cell specificity. uBriGene's platform includes CCK8-based assays for target-cell killing and tumor specificity, with additional assays selected according to the virus's mechanism of action.

Yes. uBriGene supports virus-specific analytical method development in addition to routine QC testing. This can include assays for identity, potency, infectious titer, genome titer, residuals, tumor specificity, and other product-specific quality attributes.

Downstream purification is selected according to the characteristics of the specific oncolytic virus and process. uBriGene's platform can incorporate clarification followed by purification approaches such as anion-exchange chromatography, size-exclusion chromatography, density-gradient ultracentrifugation, and tangential flow filtration (TFF), depending on product and process requirements.

Yes. uBriGene supports cell and virus banking, including Master and Working Banks, as part of its oncolytic virus CDMO platform. Qualified banks can provide controlled starting materials for process development, GMP manufacturing, and subsequent clinical production.

Need Oncolytic Virus Production?

Request a Quote